Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Gastroenterology
An Exploration of Family Centred Care (FCC) in UK Inpatient Wards
Study explores how patients, families, and nurses experience family involvement in hospital care and identifies culturally sensitive communication approaches.
31 Jul 2026 NCT07740369
● Recruiting Oncology
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
What is being tested: The role of fructose as a metabolic and inflammatory driver in MASH (metabolic dysfunction-associated steatohepatitis), investigating whether fructose specifically contributes…
31 Jul 2026 NCT07013916
● Recruiting Phase IV Oncology
Fibrosis Lessens After Metabolic Surgery
What is being tested: The trial evaluates whether metabolic surgery (such as bariatric procedures) can reduce liver fibrosis in patients with metabolic dysfunction-associated steatotic…
31 Jul 2026 NCT06374875
● Recruiting Phase II Rheumatology
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Treatment being tested: MK-8690, a novel therapeutic agent, is being evaluated for efficacy and safety in treating moderately to severely active ulcerative colitis, with…
31 Jul 2026 NCT07463183
● Recruiting Cardiology / Cardiovascular
The Oxford Risk Factors And Non-Invasive Imaging Study
What is being tested: ORFAN is developing and validating novel biomarkers for cardiometabolic disease risk by combining CT imaging data with biological material collection…
31 Jul 2026 NCT05169333
● Recruiting Oncology
Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis
What is being tested: The study investigates genetic mutations and biological factors in cancer cells that predict treatment response and resistance in adults with…
31 Jul 2026 NCT07737509
● Recruiting Phase III Oncology
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
What is being tested: TAR-210 (a novel therapeutic agent) is being compared against standard intravesical chemotherapy in BCG-treated patients with high-risk non-muscle-invasive bladder cancer…
31 Jul 2026 NCT06919965
active not recruiting Phase III Infectious Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
Two-drug long-acting injections (cabotegravir and rilpivirine) monthly maintain HIV suppression as well as daily tablets in treatment-experienced patients.
30 Jul 2026 NCT02938520
active not recruiting Diabetes / Metabolic
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
SPYRAL AFFIRM: One-sentence summary Renal denervation using Symplicity Spyral safely and effectively lowers blood pressure in patients with uncontrolled hypertension.
30 Jul 2026 NCT05198674
active not recruiting Phase III Oncology
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
New antibody-drug conjugate T-DXd, with or without pertuzumab, compared to standard chemotherapy for HER2-positive advanced breast cancer.
30 Jul 2026 NCT04784715
● Recruiting Phase I Oncology
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Drug Being Tested: ART0380, a novel therapeutic agent being evaluated for safety, tolerability, and efficacy in patients with advanced or metastatic solid tumors, with…
30 Jul 2026 NCT04657068
● Recruiting Oncology
SpaceOAR Post-Market Registry Study
What is being tested: Long-term safety profile of rectal hydrogel spacers (SpaceOAR) used during radiotherapy for prostate cancer, addressing regulatory concerns about limited post-market…
30 Jul 2026 NCT07300631
● Recruiting Oncology
Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery
What is being tested: Novel dual optical imaging systems combining OCT-Raman spectroscopy (for lumpectomy specimens) and autofluorescence-Raman spectroscopy (for sentinel lymph nodes) to provide…
30 Jul 2026 NCT06977698
● Recruiting Phase II Respiratory / COPD / Asthma
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
OATD-01 is being tested as a potential therapeutic agent for active pulmonary sarcoidosis in a Phase 2 randomized controlled trial, with assessment of efficacy,…
30 Jul 2026 NCT06205121
● Recruiting Respiratory / COPD / Asthma
Physical Activity Promotion and Clinical Remission in Severe Asthma
What is being tested: A structured physical activity promotion programme combined with tezepelumab (a biologic therapy) versus standard care alone, to determine if exercise…
30 Jul 2026 NCT07735494
● Recruiting Cardiology / Cardiovascular
Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
What is being tested: The Occlutech PDA Occluder device and delivery system for transcatheter closure of patent ductus arteriosus (PDA), with evaluation of both…
30 Jul 2026 NCT05264753
● Recruiting Cardiology / Cardiovascular
Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases
Device being tested: The Occlutech® mVSD device for percutaneous (catheter-based) closure of hemodynamically or clinically significant muscular ventricular septal defects (mVSD) as an alternative…
30 Jul 2026 NCT05329350
● Recruiting Phase II Oncology
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
What is being tested: Subcutaneous zilucoplan, a complement C5 inhibitor, is being evaluated for its pharmacokinetics, safety, tolerability, immunogenicity and clinical activity in pediatric…
30 Jul 2026 NCT06055959
active not recruiting Phase III
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
Trial testing whether leriglitazone drug slows cerebral adrenoleukodystrophy progression in adult men.
29 Jul 2026 NCT05819866
active not recruiting Phase II Oncology
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Trial testing TAR-200 drug alone or combined with cetrelimab immunotherapy versus cetrelimab alone for bladder cancer resistant to standard treatment.
29 Jul 2026 NCT04640623
active not recruiting Phase III Oncology
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Pembrolizumab plus chemotherapy before surgery, then pembrolizumab alone after surgery, improves survival in resectable lung cancer.
29 Jul 2026 NCT03425643
active not recruiting Infectious Disease
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
A rapid urine test accurately identifies bacteria causing urinary tract infections and detects antibiotic resistance.
29 Jul 2026 NCT06824129
● Recruiting
EMBRACE Tremor BiFUS
Staged bilateral focused ultrasound thalamotomy added to medication improves tremor control compared to medication alone in patients with prior unilateral treatment.
29 Jul 2026 NCT06974916
active not recruiting Phase III Oncology
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Olaparib vs placebo as maintenance therapy after chemotherapy in BRCA-mutated ovarian cancer patients.
29 Jul 2026 NCT01874353
active not recruiting Phase III Oncology
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Sacituzumab govitecan improves survival compared to standard treatment in advanced endometrial cancer patients previously treated with chemotherapy and immunotherapy.
29 Jul 2026 NCT06486441
● Recruiting Cardiology / Cardiovascular
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
What is being tested: Daily Low-methoxy (LM) pectin supplementation (a dietary polysaccharide from citrus peels) to determine whether it reduces systemic inflammation, modifies gut…
29 Jul 2026 NCT07093346
● Recruiting Phase III Respiratory / COPD / Asthma
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
What is being tested: Long-term safety, tolerability, and efficacy of seralutinib, an orally inhaled therapeutic agent, in patients with pulmonary arterial hypertension (PAH) who…
29 Jul 2026 NCT06274801
● Recruiting Oncology
BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer
What is being tested: A personalised decision support intervention (BeSpoke) that provides tailored treatment counselling to help newly diagnosed prostate cancer patients make informed…
29 Jul 2026 NCT07135271
● Recruiting Phase I Oncology
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
What is being tested: MCLA-158, a bispecific antibody, is being evaluated as a single-agent treatment in patients with advanced solid tumors, with completed dose…
29 Jul 2026 NCT03526835
active not recruiting Phase III Oncology
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
New drug volrustomig plus chemotherapy compared with pembrolizumab plus chemotherapy for advanced lung cancer with low PD-L1 levels.
28 Jul 2026 NCT05984277
active not recruiting Cardiology / Cardiovascular
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
Impella heart pump during high-risk coronary angioplasty improves symptoms and heart function in patients with weak hearts.
28 Jul 2026 NCT04763200
active not recruiting Phase III Oncology
Phase III Study of AK112 for NSCLC Patients
AK112 plus chemotherapy improved outcomes in advanced lung cancer patients whose tumours had stopped responding to targeted therapy.
28 Jul 2026 NCT06396065
active not recruiting Phase I / Phase II
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
New drug povetacicept tested in adults with autoimmune blood disorders to assess safety and effectiveness over six months.
28 Jul 2026 NCT05757570
● Recruiting Phase II
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Trial testing whether injected Corabotase into head and neck muscles safely and effectively prevents episodic or chronic migraines in adults.
28 Jul 2026 NCT06625060
active not recruiting Phase II
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Trial testing a new cancer drug (zilovertamab vedotin) alone and combined with other treatments in patients with hard-to-treat B-cell blood cancers.
28 Jul 2026 NCT05458297
● Recruiting Gastroenterology
StratCare Trial 2: Evaluating the Clinical and Cost-effectiveness of AI-driven Stratified Care for Depression
What is being tested: An AI-driven stratified care approach for depression that aims to match patients to the most appropriate treatment intensity from the…
28 Jul 2026 NCT06567340
● Recruiting Phase III Respiratory / COPD / Asthma
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
What is being tested: Depemokimab, a novel therapeutic agent, is being evaluated as an add-on treatment for moderate to severe COPD patients with Type…
28 Jul 2026 NCT07177339
● Recruiting Cardiology / Cardiovascular
Early Detection and IntervenTion in Heart Failure
What is being tested: Early detection and intervention strategies in heart failure to identify patients before symptomatic disease develops and prevent progression of cardiac…
28 Jul 2026 NCT07731490
● Recruiting Phase III Oncology
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Treatment being tested: A combination of two targeted therapies—avutometinib (a MEK inhibitor) and defactinib (a FAK inhibitor)—compared against standard investigator-selected treatments in patients with…
28 Jul 2026 NCT06072781
● Recruiting
MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)
FASTER-HIP Summary Comparing hip replacement versus surgical pinning for older adults with hip fractures, assessing effects on survival, mobility, and hospital discharge within one…
27 Jul 2026 NCT07244211
● Recruiting Phase III
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
This trial tests whether intravenous AOC 1020 safely and effectively treats facioscapulohumeral muscular dystrophy compared to placebo.
27 Jul 2026 NCT07038200
active not recruiting Phase III Oncology
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Pembrolizumab before and after surgery with radiotherapy improves survival in advanced head and neck cancer compared to radiotherapy alone.
27 Jul 2026 NCT03765918
active not recruiting Phase III Rheumatology
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
Subcutaneous anifrolumab (an interferon-blocking drug) improved outcomes in moderate-to-severe lupus patients already on standard treatment.
27 Jul 2026 NCT04877691
● Recruiting Gastroenterology
Integrating Exposure and Response Prevention and Habit Reversal Techniques to Treat a Tourettic Subtype of Obsessive-Compulsive Disorder (Tourettic OCD)
Combined exposure therapy and habit reversal training reduces symptoms better than either treatment alone in adults with obsessive-compulsive disorder and tics.
27 Jul 2026 NCT07725926
● Recruiting Phase II Neurology
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
What is being tested: Remternetug, a potential disease-modifying treatment, is being evaluated for its effectiveness in slowing cognitive decline in asymptomatic individuals at risk…
27 Jul 2026 NCT06647498
● Recruiting Phase II Neurology
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
What is being tested: Investigational disease-modifying treatments in individuals carrying genetic mutations that cause early-onset Alzheimer's disease, with evaluation of biomarker effects, safety, and…
27 Jul 2026 NCT05552157
● Recruiting Mental Health / Psychiatry
The Mouth Matters in Mental Health Trial -2
What is being tested: A link worker intervention designed to support people with severe mental health difficulties in attending routine dental appointments, with evaluation…
27 Jul 2026 NCT07470437
● Recruiting Phase III Oncology
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
What is being tested: A phase 3 randomized trial comparing two experimental combination regimens (N-803 plus tislelizumab with docetaxel, or prior failed PD-1/PD-L1 checkpoint…
27 Jul 2026 NCT06745908
● Recruiting Phase II Oncology
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Being Tested: Long-term safety, tolerability, and efficacy of adagrasib (a KRAS G12C inhibitor) as continued treatment in patients with solid tumours, predominantly NSCLC, who…
27 Jul 2026 NCT07415031
● Recruiting Phase II Oncology
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
What is being tested: Plixorafenib (FORE8394), a BRAF inhibitor, is being evaluated for efficacy and safety in patients with locally advanced, metastatic, or recurrent/progressive…
27 Jul 2026 NCT05503797